These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29329638)
1. Role of the IL-33/ST2L axis in colorectal cancer progression. Akimoto M; Takenaga K Cell Immunol; 2019 Sep; 343():103740. PubMed ID: 29329638 [TBL] [Abstract][Full Text] [Related]
2. ST2 Signaling in the Tumor Microenvironment. Chang CP; Hu MH; Hsiao YP; Wang YC Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890 [TBL] [Abstract][Full Text] [Related]
3. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment. Akimoto M; Maruyama R; Takamaru H; Ochiya T; Takenaga K Nat Commun; 2016 Nov; 7():13589. PubMed ID: 27882929 [TBL] [Abstract][Full Text] [Related]
4. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans. Pusceddu I; Dieplinger B; Mueller T Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737 [TBL] [Abstract][Full Text] [Related]
5. Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model. Takenaga K; Akimoto M; Koshikawa N; Nagase H PLoS One; 2020; 15(4):e0232230. PubMed ID: 32340025 [TBL] [Abstract][Full Text] [Related]
6. Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer. Landskron G; De la Fuente López M; Dubois-Camacho K; Díaz-Jiménez D; Orellana-Serradell O; Romero D; Sepúlveda SA; Salazar C; Parada-Venegas D; Quera R; Simian D; González MJ; López-Köstner F; Kronberg U; Abedrapo M; Gallegos I; Contreras HR; Peña C; Díaz-Araya G; Roa JC; Hermoso MA Front Immunol; 2019; 10():1394. PubMed ID: 31281317 [TBL] [Abstract][Full Text] [Related]
7. The role of IL-33/ST2L signals in the immune cells. Lu J; Kang J; Zhang C; Zhang X Immunol Lett; 2015 Mar; 164(1):11-7. PubMed ID: 25662624 [TBL] [Abstract][Full Text] [Related]
8. IL-33 Promotes the Development of Colorectal Cancer Through Inducing Tumor-Infiltrating ST2L Zhou Y; Ji Y; Wang H; Zhang H; Zhou H Technol Cancer Res Treat; 2018 Jan; 17():1533033818780091. PubMed ID: 29950152 [TBL] [Abstract][Full Text] [Related]
9. Dynamic observation of IL-33 and its receptors in HIV patients who received HAART. He B; Zheng L; Zhou H; He Y; Chen Z; Xiao S; Wang H; Ling Y; Zheng Y Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):73-77. PubMed ID: 28466817 [TBL] [Abstract][Full Text] [Related]
10. IL-13 Controls IL-33 Activity through Modulation of ST2. Zhang M; Duffen JL; Nocka KH; Kasaian MT J Immunol; 2021 Dec; 207(12):3070-3080. PubMed ID: 34789557 [TBL] [Abstract][Full Text] [Related]
11. The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasis. Zhou Q; Wu X; Wang X; Yu Z; Pan T; Li Z; Chang X; Jin Z; Li J; Zhu Z; Liu B; Su L Oncogene; 2020 Feb; 39(7):1414-1428. PubMed ID: 31659258 [TBL] [Abstract][Full Text] [Related]
12. ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis. Cui G; Yuan A; Li Z; Goll R; Florholmen J Sci Rep; 2020 Apr; 10(1):5892. PubMed ID: 32246094 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia induces downregulation of the tumor-suppressive sST2 in colorectal cancer cells via the HIF-nuclear IL-33-GATA3 pathway. Akimoto M; Susa T; Okudaira N; Koshikawa N; Hisaki H; Iizuka M; Okinaga H; Takenaga K; Okazaki T; Tamamori-Adachi M Proc Natl Acad Sci U S A; 2023 May; 120(18):e2218033120. PubMed ID: 37094129 [TBL] [Abstract][Full Text] [Related]
14. Soluble ST2: A complex and diverse role in several diseases. Homsak E; Gruson D Clin Chim Acta; 2020 Aug; 507():75-87. PubMed ID: 32305537 [TBL] [Abstract][Full Text] [Related]
15. The IL-33/ST2 axis: Role in health and disease. De la Fuente M; MacDonald TT; Hermoso MA Cytokine Growth Factor Rev; 2015 Dec; 26(6):615-23. PubMed ID: 26271893 [TBL] [Abstract][Full Text] [Related]
16. IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics. Mitchell PD; Salter BM; Oliveria JP; El-Gammal A; Tworek D; Smith SG; Sehmi R; Gauvreau GM; O Apos Byrne PM Int Arch Allergy Immunol; 2018; 176(2):133-142. PubMed ID: 29694974 [TBL] [Abstract][Full Text] [Related]
17. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. O'Donnell C; Mahmoud A; Keane J; Murphy C; White D; Carey S; O'Riordain M; Bennett MW; Brint E; Houston A Br J Cancer; 2016 Jan; 114(1):37-43. PubMed ID: 26679377 [TBL] [Abstract][Full Text] [Related]
18. The biology of ST2: the International ST2 Consensus Panel. Pascual-Figal DA; Januzzi JL Am J Cardiol; 2015 Apr; 115(7 Suppl):3B-7B. PubMed ID: 25665766 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Beltrán CJ; Núñez LE; Díaz-Jiménez D; Farfan N; Candia E; Heine C; López F; González MJ; Quera R; Hermoso MA Inflamm Bowel Dis; 2010 Jul; 16(7):1097-107. PubMed ID: 20014018 [TBL] [Abstract][Full Text] [Related]
20. Soluble ST2 suppresses IL-5 production by human basophilic KU812 cells, induced by epithelial cell-derived IL-33. Matsumoto K; Kouzaki H; Kikuoka H; Kato T; Tojima I; Shimizu S; Shimizu T Allergol Int; 2018 Sep; 67S():S32-S37. PubMed ID: 29941231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]